Literature DB >> 1788265

Serotonin immunoreactivity in pancreatic endocrine neoplasms (carcinoid tumors).

R W Wilson1, A A Gal, C Cohen, P B DeRose, W J Millikan.   

Abstract

Primary serotonin secreting pancreatic endocrine neoplasms (carcinoid tumors) are extremely rare and may be associated with manifestations of the carcinoid syndrome. Two cases of primary carcinoid tumor of the pancreas with liver metastases showed clinical and biochemical features of the carcinoid syndrome. Both cases demonstrated strong positive immunoreactivity for serotonin within the tumor cells. In an attempt to determine the relationship between pancreatic carcinoid tumors and other pancreatic endocrine neoplasms, immunostains for serotonin were performed on 11 additional islet cell tumors and on non-neoplastic pancreatic tissues. These cases showed serotonin immunoreactivity within islet cell tumors (36%). In addition, focal staining for serotonin was present in non-neoplastic ducts and ductules (88%), acini (22%), and islets of Langerhans (33%). Based on these observations, specific criteria are suggested for the diagnosis of primary pancreatic carcinoid tumor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1788265

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  3 in total

Review 1.  Carcinoid tumors of the pancreas. Status report based on two cases and review of the world's literature.

Authors:  C Mao; A el Attar; D R Domenico; K Kim; J M Howard
Journal:  Int J Pancreatol       Date:  1998-04

2.  Pancreatic duct stenosis secondary to small endocrine neoplasms: a manifestation of serotonin production?

Authors:  Chanjuan Shi; Stanley S Siegelman; Satomi Kawamoto; Christopher L Wolfgang; Richard D Schulick; Anirban Maitra; Ralph H Hruban
Journal:  Radiology       Date:  2010-08-16       Impact factor: 11.105

3.  Serotonin-Secreting Neuroendocrine Tumours of the Pancreas.

Authors:  Anna Caterina Milanetto; Matteo Fassan; Alina David; Claudio Pasquali
Journal:  J Clin Med       Date:  2020-05-06       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.